Kura Oncology Inc (KURA) Receives Consensus Rating of “Buy” from Analysts

Kura Oncology Inc (NASDAQ:KURA) has received a consensus recommendation of “Buy” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $28.33.

A number of equities analysts have recently commented on the stock. BidaskClub raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. Oppenheimer set a $32.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday. Zacks Investment Research lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, November 9th. Piper Jaffray Companies assumed coverage on shares of Kura Oncology in a research report on Friday, November 9th. They set an “overweight” rating and a $25.00 target price on the stock. Finally, HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Thursday, November 1st.

Shares of NASDAQ:KURA traded up $0.25 during trading on Friday, reaching $12.70. 115,742 shares of the company were exchanged, compared to its average volume of 187,471. The firm has a market cap of $483.07 million, a PE ratio of -8.36 and a beta of 4.39. Kura Oncology has a 12-month low of $10.20 and a 12-month high of $24.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.76 and a current ratio of 14.76.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, November 5th. The company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.01. Equities research analysts predict that Kura Oncology will post -1.72 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. purchased a new position in Kura Oncology during the second quarter valued at approximately $2,412,000. Swiss National Bank purchased a new position in Kura Oncology during the second quarter valued at approximately $768,000. Prosight Management LP purchased a new position in Kura Oncology during the second quarter valued at approximately $5,240,000. BlackRock Inc. increased its holdings in Kura Oncology by 25.5% during the second quarter. BlackRock Inc. now owns 2,002,265 shares of the company’s stock valued at $36,440,000 after buying an additional 406,963 shares during the period. Finally, Sio Capital Management LLC increased its holdings in Kura Oncology by 27.4% during the second quarter. Sio Capital Management LLC now owns 837,604 shares of the company’s stock valued at $15,244,000 after buying an additional 180,193 shares during the period. 79.99% of the stock is currently owned by institutional investors.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Different Types of Derivatives

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit